Atlas Trials

Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma

Clinical trial NCT02902965 · COMPLETED

Trial details

NCT number
NCT02902965
Sponsor
Pharmacyclics Switzerland GmbH
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2016-09-20
Primary completion
2018-10-26
Enrollment
74

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.